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a b s t r a c t
Alzheimer's disease (AD) is a neurodegenerative disorder with a progressive cognitive decline and
memory loss. Multiple pathogenetic factors including aggregated β-amyloid (Aβ), neuroﬁbrillary tangles
(NFTs), cholinergic dysfunction and oxidative stress are involved in AD. Aβ, a major constituent of the
senile plaques, is a potent neurotoxic peptide and has a pivotal role in cognitive deﬁcit and reduced
synaptic plasticity in AD. In the present study we examined the protective effect of troxerutin, as a
multipotent bioﬂavonoid, on Aβ (1–42)-induced impairment of evoked ﬁeld potential in hippocampal
DG neurons. Male Wistar rats were divided into four groups including Aβ (42–1), Aβ (1–42), Aβ (1–42)
plus troxerutin and Aβ (42–1) plus troxerutin groups. Aβ was injected intracerebroventricularly (i.c.v.)
into right lateral ventricle and after two weeks the evoked ﬁeld potential recorded from perforant path-
DG synapses to assess paired pulse paradigm and long term potentiation (LTP). Administration of
Aβ (1–42) drastically attenuated the LTP of DG neurons, while there was no signiﬁcant difference in
evoked ﬁeld potentials between Aβ (1–42) plus troxerutin group with respect to Aβ (42–1) group. This
study revealed that troxerutin improves the synaptic failure induced by Aβ peptide and can be introduced
as a promising multi-potent pharmacological agent in prevention or treatment of AD in the future.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Accumulation of amyloid-beta peptide (Aβ) in the brain of
patient with Alzheimer's disease (AD) leads to neuronal dysfunc-
tion and cognitive deﬁcits (Selkoe, 2001). Memory deﬁcit in AD
begins with changes in hippocampal synaptic functions and then
gradually promotes toward subsequent neurodegeneration and
neuronal loss in these patients (Selkoe, 2002). A main form of
synaptic plasticity is long-term potentiation (LTP) which is an
activity-dependent increase in synaptic efﬁciency. Hippocampal
LTP is well recognized as a cellular basis of learning and memory
and provides an attractive means of detecting any changes in
synaptic function (Namgung et al., 1995). Surveys conducted by
previous researchers have shown that LTP undergoes changes
by Aβ in the hippocampus resulting in cognitive dysfunction and
impairment of learning and memory (Babri et al., 2012a; Selkoe,
2008).
Multiple factors such as Aβ aggregation, the formation of
neuroﬁbrillary tangles (NFTs), cholinergic dysfunction, inﬂamma-
tory agents, oxidative stress and glutamate-mediated excitotoxi-
city are involved in the pathogenesis of AD, the factors can act
somehow to alter the synaptic efﬁcacy (Querfurth and LaFerla,
2010). Previous strategies to combat AD have led to discovering
drugs aimed at single targets, e.g. β-secretase, N-methyl-D-aspar-
tate (NMDA) receptors, acetylcholinesterase (AChE) enzyme and
reactive oxygen species and a little attention has been paid to
introduce a multipotent agent aiming at different targets (Francis
et al., 2010; Li et al., 2010). The recent studies have emerged that
using natural products especially the ﬂavonoids which possess
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